Bente Halvorsen1, Linda M Smedbakken2, Annika E Michelsen2, Mona Skjelland3, Vigdis Bjerkeli2, Ellen Lund Sagen2, Kjetil Taskén4, Bjørn Bendz5, Lars Gullestad6, Sverre Holm7, Erik A Biessen8, Pål Aukrust9. 1. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: Bente.Halvorsen@rr-research.no. 2. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3. Department of Neurology, Oslo University Hospital Rikshospitalet, Oslo, Norway. 4. Department of Infectious Diseases, Oslo University Hospital Ullevål, Oslo, Norway; Centre for Molecular Medicine Norway, Nordic EMBL Partnership and Biotechnology Centre, Oslo University Hospital and University of Oslo, Oslo, Norway; Biotechnology Centre, University of Oslo, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway. 5. Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway. 6. Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 7. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 8. Department of Pathology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, Netherlands. 9. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Inflammation Research Center, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects. OBJECTIVE: To investigate the regulation of CXCL13s receptor, CXCR5. METHODS/PATIENTS: In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). RESULTS: Our major findings were: (i) toll-like receptor agonists and particularly β-adrenergic receptor activation and releasate from thrombin-activated platelets increased CXCR5 mRNA levels in monocytes. (ii) The platelet-mediated induction of CXCR5 involved prostaglandin E2/cAMP/protein kinase A-dependent as well as RANTES-dependent pathways with NFκB activation as a potential common down-stream mediator. (iii) Releasate from thrombin-activated platelets augmented the anti-inflammatory effects of CXCL13 in monocytes at least partly by enhancing the effects of CXCL13 on CXCR5 expression. (iv) We found strong immunostaining of CXCR5 in thrombus material obtained at the site of plaque rupture in patients with ST elevation MI (STEMI) and in unstable carotid lesions, co-localized with platelets. CONCLUSION: Our findings suggest that platelet-mediated signaling through CXCR5 may be active in vivo during plaque destabilization, potentially representing a counteracting mechanism to inflammation.
BACKGROUND: We have previously shown that the homeostatic chemokine CXCL13 is up-regulated in monocytes in atherosclerosis, mediating anti-apoptotic and anti-inflammatory effects. OBJECTIVE: To investigate the regulation of CXCL13s receptor, CXCR5. METHODS/PATIENTS: In vitro studies in THP-1 and primary monocytes and studies of CXCR5 expression in thrombus material obtained at the site of plaque rupture during myocardial infarction (MI). RESULTS: Our major findings were: (i) toll-like receptor agonists and particularly β-adrenergic receptor activation and releasate from thrombin-activated platelets increased CXCR5 mRNA levels in monocytes. (ii) The platelet-mediated induction of CXCR5 involved prostaglandin E2/cAMP/protein kinase A-dependent as well as RANTES-dependent pathways with NFκB activation as a potential common down-stream mediator. (iii) Releasate from thrombin-activated platelets augmented the anti-inflammatory effects of CXCL13 in monocytes at least partly by enhancing the effects of CXCL13 on CXCR5 expression. (iv) We found strong immunostaining of CXCR5 in thrombus material obtained at the site of plaque rupture in patients with ST elevation MI (STEMI) and in unstable carotid lesions, co-localized with platelets. CONCLUSION: Our findings suggest that platelet-mediated signaling through CXCR5 may be active in vivo during plaque destabilization, potentially representing a counteracting mechanism to inflammation.
Authors: Brian M Wei; Douglas Hanlon; David Khalil; Patrick Han; Kazuki Tatsuno; Olga Sobolev; Richard L Edelson Journal: Yale J Biol Med Date: 2020-03-27
Authors: Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Kevin G McLure; Peter R Young; Allan Gordon; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C Wong Journal: Data Brief Date: 2016-07-29